References
- HunterPRNicholsGEpidemiology and clinical features of cryptosporidium infection in immunocompromised patientsClin Microbiol Rev200215114515411781272
- Laniado-LaborínRCabrales-VargasMNAmphotericin B: side effects and toxicityRev Iberoam Micol200926422322719836985
- PathakAPienFDCarvalhoLAmphotericin B use in a community hospital, with special emphasis on side effectsClinic Infect Dis1998262334338
- Ostrosky-ZeichnerLMartKARexJHCohenSHAmphotericin B: time for a new “gold standard”Clin Infect Dis200337341544212884167
- TonomuraYYamamotoEKondoCAmphotericin B-induced nephrotoxicity: characterization of blood and urinary biochemistry and renal morphology in miceHum Exp Toxicol200928529330019661263
- RamaswamyMPeteherychKDKennedyALWasanKMAmphotericin B lipid complex or amphotericin B multiple-dose administration to rabbits with elevated plasma cholesterol levels: pharmacokinetics in plasma and blood, plasma lipoprotein levels, distribution in tissues, and renal toxicitiesAntimicrob Agents Chemother20014541184119111257033
- SubiràMMartinoRGómezLLow-dose amphotericin B lipid complex vs conventional amphotericin B for empirical antifungal therapy of neutropenic fever in patients with hematologic malignancies: a randomized, controlled trialEur J Haematol200472534234715059069
- KulkarniPVRoneyCAAntichPPQuinoline-n-butylcyanoacrylate-based nanoparticles for brain targeting for the diagnosis of Alzheimer’s diseaseWiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology201021354720049829
- KreuterJGelperinaSUse of nanoparticles for cerebral cancerTumori200894227127718564616
- DasDLinSDouble-coated poly (butylcynanoacrylate) nanoparticulate delivery systems for brain targeting of dalargin via oral administrationJ Pharm Sci20059461343135315858853
- AmbruosiAYamamotoHKreuterJBody distribution of polysorbate-80 and doxorubicin-loaded [14C] poly(butyl cyanoacrylate) nanoparticles after i.v. administration in ratsJ Drug Target2005131053554216390814
- KuoYCSuFLTransport of stavudine, delavirdine, and saquinavir across the blood-brain barrier by polybutylcyanoacrylate, methyl-methacrylate-sulfopropylmethacrylate, and solid lipid nanoparticlesInt J Pharmaceut20073401–2143152
- RamgePUngerREOltroggeJBPolysorbate-80 coating enhances uptake of polybutylcyanoacrylate (PBCA)-nanoparticles by human and bovine primary brain capillary endothelial cellsEur J Neurosci20001261931194010886334
- KreuterJRamgePPetrovVDirect evidence that polysorbate-80-coated poly(butylcyanoacrylate) nanoparticles deliver drugs to the CNS via specific mechanisms requiring prior binding of drug to the nanoparticlesPharmaceut Res2003203409416
- RenTBXuNCaoCPreparation and therapeutic efficacy of polysorbate-80-coated amphotericin B/PLA-b-PEG nanoparticlesJ Biomater Sci Polym Ed200920101369138019622277
- GallisHADrewRHPickardWWAmphotericin B:30 years of clinical experienceRev Infect Dis1990123083292184499
- BaginskiMCzubJAmphotericin B and its new derivatives: mode of actionCurr Drug Metab200910545946919689243
- BarrattGBretagneSOptimizing efficacy of amphotericin B through nanomodificationInt J Nanomedicine20072330131318019830
- KreuterJAlyautdinRNKharkevichDAPassage of peptides through the blood-brain barrier with colloidal polymer particles (nanoparticles)Brain Res199567411711747773690
- KreuterJApplication of nanoparticles for the delivery of drugs to the brainInt Congr Ser200512778594
- KreuterJHekmataraTDreisaSCovalent attachment of ApoA-I and ApoB-100 to albumin nanoparticles enables drug transport into the brainJ Control Release2007118545817250920
- CouvreurPKanteBRolandMPoly(cyanoacrylate) nanocapsules as potential lysosomotropic carriers: preparation, morphological and sorptive propertiesJ Pharm Pharmacol19793133133237304